Pancreatic cancer cachexia: A review of mechanisms and therapeutics

Frontiers in Physiology

Volumn 5 MAR, Issue , 2014, Pages

  Tan, Carlyn R ^a   Yaffee, Patrick M ^a   Jamil, Laith H ^b   Lo, Simon K ^a   Nissen, Nicholas ^a   Pandol, Stephen J ^a   Tuli, Richard ^a   Hendifar, Andrew E ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anorexia; Cachexia; Catabolism; Multimodal therapy; Pancreatic cancer

Indexed keywords

ANTIINFLAMMATORY AGENT; BYM 338; BYM338; CARNITINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; DRONABINOL; GESTAGEN; IBUPROFEN; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 6; LY 2495655; LY2495655; MEGESTROL ACETATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; THALIDOMIDE; TRANSCRIPTION FACTOR PAX7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADRENAL CORTEX INSUFFICIENCY; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ASCITES; CACHEXIA; CANCER PAIN; CARDIOVASCULAR DISEASE; CATABOLISM; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONSTIPATION; CYTOKINE PRODUCTION; DIZZINESS; DUODENUM STENOSIS; DYSPHAGIA; ENERGY METABOLISM; EUPHORIA; FATIGUE; FOOD INTAKE; HALLUCINATION; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; INFLAMMATION; INSULIN RESISTANCE; MALABSORPTION; MULTIMODALITY CANCER THERAPY; MYOPATHY; NAUSEA; NONHUMAN; NUTRITIONAL SUPPORT; PANCREAS CANCER; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PSYCHOSIS; RASH; REVIEW; SKIN FRAGILITY; SLEEP DISORDER; SOMNOLENCE; STOMACH PARESIS; SYMPTOMATOLOGY; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84897938190     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00088     Document Type: Review

References (152)

1. Ando, K., Takahashi, F., Motojima, S., Nakashima, K., Kaneko, N., Hoshi, K., et al. (2013). Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31, e69-e72. doi: 10.1200/JCO.2012.44.2020.
2. Arruda, A. P., Milanski, M., Romanatto, T., Solon, C., Coope, A., Alberici, L. C., et al. (2010). Hypothalamic actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology 151, 683-694. doi: 10.1210/en.2009-0865.
3. Bachmann, J., Heiligensetzer, M., Krakowski-Roosen, H., Büchler, M. W., Friess, H., and Martignoni, M. E. (2008). Cachexia worsens prognosis in patients with resectable pancreatic cancer. J. Gastrointest. Surg. 12, 1193-1201. doi: 10.1007/s11605-008-0505-z.
4. Bachmann, J., Ketterer, K., Marsch, C., Fechtner, K., Krakowski-Roosen, H., Buchler, M. W., et al. (2009). Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 9:255. doi: 10.1186/1471-2407-9-255.
5. Barber, M. D., Ross, J. A., Voss, A. C., Tisdale, M. J., and Fearon, K. C. (1999). The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br. J. Cancer 81, 80-86. doi: 10.1038/sj.bjc.6690654.
6. Bauer, J. D., and Capra, S. (2005). Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy-a pilot study. Support. Care Cancer 13, 270-274. doi: 10.1007/s00520-004-0746-7.
7. Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H., and Rigas, J. R. (2011). A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin. Biol. Ther. 11, 1663-1668. doi: 10.1517/14712598.2011.627850.
8. Bing, C., Russell, S. T., Beckett, E. E., Collins, P., Taylor, S., Barraclough, R., et al. (2002). Expression of uncoupling proteins-1,-2 and-3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br. J. Cancer 86, 612-618. doi: 10.1038/sj.bjc.6600101.
9. Bing, C., Taylor, S., Tisdale, M. J., and Williams, G. (2001). Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J. Neurochem. 79, 1004-1012. doi: 10.1046/j.1471-4159.2001.00639.x.
10. Bozzetti, F., and Group, S. W. (2009). Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support. Care Cancer 17, 279-284. doi: 10.1007/s00520-008-0476-3.
11. Bruera, E., MacMillan, K., Kuehn, N., Hanson, J., and MacDonald, R. N. (1990). A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66, 1279-1282. doi: 10.1002/1097-0142(19900915)66:6%3C1279::AID-CNCR2820660630%3E3.0.CO;2-R.
12. Bruera, E., Neumann, C. M., Pituskin, E., Calder, K., Ball, G., and Hanson, J. (1999). Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann. Oncol. 10, 857-859. doi: 10.1023/A:1008329821941.
13. Bruera, E., Roca, E., Cedaro, L., Carraro, S., and Chacon, R. (1985). Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat. Rep. 69, 751-754.
14. Bruera, E., and Sweeney, C. (2000). Cachexia and asthenia in cancer patients. Lancet Oncol. 1, 138-147. doi: 10.1016/S1470-2045(00)00033-4.
15. Cabal-Manzano, R., Bhargava, P., Torres-Duarte, A., Marshall, J., and Wainer, I. W. (2001). Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br. J. Cancer 84, 1599-1601. doi: 10.1054/bjoc.2001.1830.
16. Cangiano, C., Cascino, A., Ceci, F., Laviano, A., Mulieri, M., Muscaritoli, M., et al. (1990). Plasma and CSF tryptophan in cancer anorexia. J. Neural Transm. Gen. Sect. 81, 225-233. doi: 10.1007/BF01245044.
17. Cangiano, C., Testa, U., Muscaritoli, M., Meguid, M. M., Mulieri, M., Laviano, A., et al. (1994). Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation. Anticancer Res. 14, 1451-1455.
18. Cariuk, P., Lorite, M. J., Todorov, P. T., Field, W. N., Wigmore, S. J., and Tisdale, M. J. (1997). Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br. J. Cancer 76, 606-613. doi: 10.1038/bjc.1997.433.
19. Castell, J. V., Gómez-Lechón, M. J., David, M., Fabra, R., Trullenque, R., and Heinrich, P. C. (1990). Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12, 1179-1186. doi: 10.1002/hep.1840120517.
20. Cawthorn, W. P., Heyd, F., Hegyi, K., and Sethi, J. K. (2007). Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ. 14, 1361-1373. doi: 10.1038/sj.cdd.4402127.
21. Chasen, M., Hirschman, S. Z., and Bhargava, R. (2011). Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J. Am. Med. Dir. Assoc. 12, 62-67. doi: 10.1016/j.jamda.2010.02.012.
22. ClinicalTrials.gov. A Phase 2 study of LY2495655 in participants with pancreatic cancer. Available online at: http://clinicaltrials.gov/ct2/show/NCT01505530. (Accessed December 2013).
23. ClinicalTrials.gov. Clinical study of BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas. Available online at: http://clinicaltrials.gov/ct2/show/NCT01433263. (Accessed December 2013).
24. ClinicalTrials.gov. Open label study with OHR/AVR118 in advanced cancer patients with anorexia-cachexia. Available online at: http://clinicaltrials.gov/ct2/show/NCT01206335. (Accessed December 2013).
25. Cunningham, T. J., Jing, H., Akerblom, I., Morgan, R., Fisher, T. S., and Neveu, M. (2002). Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp. Neurol. 177, 32-39. doi: 10.1006/exnr.2002.7979.
26. Dahele, M., Skipworth, R. J., Wall, L., Voss, A., Preston, T., and Fearon, K. C. (2007). Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J. Pain Symptom Manage. 33, 676-685. doi: 10.1016/j.jpainsymman.2006.09.024.
27. Deutsch, J., and Kolhouse, J. F. (2004). Assessment of gastrointestinal function and response to megesterol acetate in subjects with gastrointestinal cancers and weight loss. Support. Care Cancer 12, 503-510. doi: 10.1007/s00520-004-0615-4.
28. DeWys, W. D. (1979). Anorexia as a general effect of cancer. Cancer 43, 2013-2019. doi: 10.1002/1097-0142(197905)43:5+%3C2013::AID-CNCR2820430709%3E3.0.CO;2-Z.
29. Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., et al. (1980). Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69, 491-497. doi: 10.1016/S0149-2918(05)80001-3.
30. Di Sebastiano, K. M., and Mourtzakis, M. (2012). A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl. Physiol. Nutr. Metab. 37, 811-821. doi: 10.1139/h2012-079.
31. Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., and Kurzrock, R. (2004). Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101, 2727-2736. doi: 10.1002/cncr.20672.
32. Eley, H. L., and Tisdale, M. J. (2007). Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282, 7087-7097. doi: 10.1074/jbc.M610378200.
33. el-Kamar, F. G., Grossbard, M. L., and Kozuch, P. S. (2003). Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 8, 18-34. doi: 10.1634/theoncologist.8-1-18.
34. Faggioni, R., Fuller, J., Moser, A., Feingold, K. R., and Grunfeld, C. (1997). LPS-induced anorexia in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice. Am. J. Physiol. 273, R181-R186.
35. Fearon, K., Arends, J., and Baracos, V. (2013). Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10, 90-99. doi: 10.1038/nrclinonc.2012.209.
36. Fearon, K. C. (2008). Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur. J. Cancer 44, 1124-1132. doi: 10.1016/j.ejca.2008.02.033.
37. Fearon, K. C. (2012). The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes. Clin. Nutr. 31, 577-582. doi: 10.1016/j.clnu.2012.06.012.
38. Fearon, K. C., Barber, M. D., Falconer, J. S., McMillan, D. C., Ross, J. A., and Preston, T. (1999). Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J. Surg. 23, 584-588. doi: 10.1007/PL00012351.
39. Fearon, K. C., Barber, M. D., Moses, A. G., Ahmedzai, S. H., Taylor, G. S., Tisdale, M. J., et al. (2006a). Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol. 24, 3401-3407. doi: 10.1200/JCO.2005.04.5724.
40. Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., et al. (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489-495. doi: 10.1016/S1470-2045(10)70218-7.
41. Fearon, K. C., Von Meyenfeldt, M. F., Moses, A. G., Van Geenen, R., Roy, A., Gouma, D. J., et al. (2003). Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479-1486. doi: 10.1136/gut.52.10.1479.
42. Fearon, K. C., Voss, A. C., Hustead, D. S., and Group, C. C. (2006b). Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 83, 1345-1350.
43. Felix, K., Fakelman, F., Hartmann, D., Giese, N. A., Gaida, M. M., Schnölzer, M., et al. (2011). Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci. 88, 218-225. doi: 10.1016/j.lfs.2010.11.011.
44. Finck, B. N., Kelley, K. W., Dantzer, R., and Johnson, R. W. (1998). In vivo and in vitro evidence for the involvement of tumor necrosis factor-alpha in the induction of leptin by lipopolysaccharide. Endocrinology 139, 2278-2283. doi: 10.1210/endo.139.5.6012.
45. Gelin, J., Andersson, C., and Lundholm, K. (1991a). Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 51, 880-885.
46. Gelin, J., Moldawer, L. L., Lönnroth, C., Sherry, B., Chizzonite, R., and Lundholm, K. (1991b). Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51, 415-421.
47. Gordon, J. N., Trebble, T. M., Ellis, R. D., Duncan, H. D., Johns, T., and Goggin, P. M. (2005). Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540-545. doi: 10.1136/gut.2004.047563.
48. Grunfeld, C., Zhao, C., Fuller, J., Pollack, A., Moser, A., Friedman, J., et al. (1996). Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J. Clin. Invest. 97, 2152-2157. doi: 10.1172/JCI118653.
49. Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C. Y., and Baldwin, A. S. (2000). NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289, 2363-2366. doi: 10.1126/science.289.5488.2363.
50. Hammarstedt, A., Isakson, P., Gustafson, B., and Smith, U. (2007). Wnt-signaling is maintained and adipogenesis inhibited by TNFalpha but not MCP-1 and resistin. Biochem. Biophys. Res. Commun. 357, 700-706. doi: 10.1016/j.bbrc.2007.03.202.
51. He, W. A., Berardi, E., Cardillo, V. M., Acharyya, S., Aulino, P., Thomas-Ahner, J., et al. (2013). NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123, 4821-4835. doi: 10.1172/JCI68523.
52. Heisler, L. K., Cowley, M. A., Tecott, L. H., Fan, W., Low, M. J., Smart, J. L., et al. (2002). Activation of central melanocortin pathways by fenfluramine. Science 297, 609-611. doi: 10.1126/science.1072327.
53. Hirai, K., Hussey, H. J., Barber, M. D., Price, S. A., and Tisdale, M. J. (1998). Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 58, 2359-2365.
54. Hussey, H. J., and Tisdale, M. J. (1999). Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Br. J. Cancer 80, 1231-1235. doi: 10.1038/sj.bjc.6690490.
55. Imoto, A., Mitsunaga, S., Inagaki, M., Aoyagi, K., Sasaki, H., Ikeda, M., et al. (2012). Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer. Int. J. Cancer 131, 2795-2807. doi: 10.1002/ijc.27594.
56. Inui, A. (1999). Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 59, 4493-4501.
57. Islam-Ali, B., Khan, S., Price, S. A., and Tisdale, M. J. (2001). Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br. J. Cancer 85, 758-763. doi: 10.1054/bjoc.2001.1992.
58. Janik, J. E., Curti, B. D., Considine, R. V., Rager, H. C., Powers, G. C., Alvord, W. G., et al. (1997). Interleukin 1 alpha increases serum leptin concentrations in humans. J. Clin. Endocrinol. Metab. 82, 3084-3086. doi: 10.1210/jcem.82.9.4214.
59. Jatoi, A., and Loprinzi, C. L. (2001). Current management of cancer-associated anorexia and weight loss. Oncology (Williston Park) 15, 497-502, 508. discussion: 508-510.
60. Jatoi, A., Rowland, K., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., MacDonald, N., et al. (2004). An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J. Clin. Oncol. 22, 2469-2476. doi: 10.1200/JCO.2004.06.024.
61. Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol. 20, 567-573. doi: 10.1200/JCO.20.2.567.
62. Karayiannakis, A. J., Syrigos, K. N., Polychronidis, A., Pitiakoudis, M., Bounovas, A., and Simopoulos, K. (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 21, 1355-1358.
63. Khan, S., and Tisdale, M. J. (1999). Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int. J. Cancer 80, 444-447. doi: 10.1002/(SICI)1097-0215(19990129)80:3%3C444::AID-IJC18%3E3.3.CO;2-L.
64. Kraft, M., Kraft, K., Gartner, S., Mayerle, J., Simon, P., Weber, E., et al. (2012). L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)-a randomized multicentre trial. Nutr. J. 11:52. doi: 10.1186/1475-2891-11-52.
65. Lai, V., George, J., Richey, L., Kim, H. J., Cannon, T., Shores, C., et al. (2008). Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 30, 67-74. doi: 10.1002/hed.20662.
66. Laviano, A., Meguid, M. M., and Rossi-Fanelli, F. (2003). Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol. 4, 686-694. doi: 10.1016/S1470-2045(03)01247-6.
67. Lesniak, W., Bala, M., Jaeschke, R., and Krzakowski, M. (2008). Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome-a systematic review and meta-analysis. Pol. Arch. Med. Wewn. 118, 636-644.
68. Li, G., Klein, R. L., Matheny, M., King, M. A., Meyer, E. M., and Scarpace, P. J. (2002). Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 115, 879-889. doi: 10.1016/S0306-4522(02)00447-5.
69. Li, Y. P., and Reid, M. B. (2000). NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1165-R1170.
70. Llovera, M., Carbó, N., López-Soriano, J., García-Martínez, C., Busquets, S., Alvarez, B., et al. (1998). Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 133, 83-87. doi: 10.1016/S0304-3835(98)00216-X.
71. Loprinzi, C. L., Ellison, N. M., Schaid, D. J., Krook, J. E., Athmann, L. M., Dose, A. M., et al. (1990). Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J. Natl. Cancer Inst. 82, 1127-1132. doi: 10.1093/jnci/82.13.1127.
72. Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., Krook, J. E., Wilwerding, M. B., et al. (1999). Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol. 17, 3299-3306.
73. Loprinzi, C. L., Michalak, J. C., Schaid, D. J., Mailliard, J. A., Athmann, L. M., Goldberg, R. M., et al. (1993a). Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J. Clin. Oncol. 11, 762-767.
74. Loprinzi, C. L., Schaid, D. J., Dose, A. M., Burnham, N. L., and Jensen, M. D. (1993b). Body-composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol. 11, 152-154.
75. Lorite, M. J., Cariuk, P., and Tisdale, M. J. (1997). Induction of muscle protein degradation by a tumour factor. Br. J. Cancer 76, 1035-1040. doi: 10.1038/bjc.1997.504.
76. Lorite, M. J., Smith, H. J., Arnold, J. A., Morris, A., Thompson, M. G., and Tisdale, M. J. (2001). Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br. J. Cancer 85, 297-302. doi: 10.1054/bjoc.2001.1879.
77. Lundholm, K., Gelin, J., Hyltander, A., Lönnroth, C., Sandström, R., Svaninger, G., et al. (1994). Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54, 5602-5606.
78. Maltoni, M., Fabbri, L., Nanni, O., Scarpi, E., Pezzi, L., Flamini, E., et al. (1997). Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5, 130-135. doi: 10.1007/BF01262570.
79. Mantovani, G., Macciò, A., Lai, P., Massa, E., Ghiani, M., and Santona, M. C. (1998a). Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol. 25(2 Suppl. 6), 45-52.
80. Mantovani, G., Macciò, A., Lai, P., Massa, E., Ghiani, M., and Santona, M. C. (1998b). Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit. Rev. Oncog. 9, 99-106. doi: 10.1615/CritRevOncog.v9.i2.10.
81. Mantovani, G., Macciò, A., Madeddu, C., Serpe, R., Massa, E., Dessì, M., et al. (2010). Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15, 200-211. doi: 10.1634/theoncologist.2009-0153.
82. Mantovani, G., Macciò, A., Mura, L., Massa, E., Mudu, M. C., Mulas, C., et al. (2000). Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. (Berl.) 78, 554-561. doi: 10.1007/s001090000137.
83. Marks, D., and Cone, R. D. (2003). The role of the melanocortin-3 receptor in cachexia. Ann. N.Y. Acad. Sci. 994, 258-266. doi: 10.1111/j.1749-6632.2003.tb03188.x.
84. Marks, D. L., Butler, A. A., Turner, R., Brookhart, G., and Cone, R. D. (2003). Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144, 1513-1523. doi: 10.1210/en.2002-221099.
85. Martignoni, M. E., Dimitriu, C., Bachmann, J., Krakowski-Rosen, H., Ketterer, K., Kinscherf, R., et al. (2009). Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol. Rep. 21, 363-369. doi: 10.3892/or_00000231.
86. Martignoni, M. E., Kunze, P., Hildebrandt, W., Künzli, B., Berberat, P., Giese, T., et al. (2005). Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin. Cancer Res. 11, 5802-5808. doi: 10.1158/1078-0432.CCR-05-0185.
87. McCarthy, H. D., Crowder, R. E., Dryden, S., and Williams, G. (1994). Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur. J. Pharmacol. 265, 99-102. doi: 10.1016/0014-2999(94)90229-1.
88. McMillan, D. C., Leen, E., Smith, J., Sturgeon, C., Preston, T., Cooke, T. G., et al. (1995). Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur. J. Surg. Oncol. 21, 531-534. doi: 10.1016/S0748-7983(95)97157-2.
89. McMillan, D. C., O'Gorman, P., Fearon, K. C., and McArdle, C. S. (1997). A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br. J. Cancer 76, 788-790. doi: 10.1038/bjc.1997.463.
90. McMillan, D. C., Wigmore, S. J., Fearon, K. C., O'Gorman, P., Wright, C. E., and McArdle, C. S. (1999). A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br. J. Cancer 79, 495-500. doi: 10.1038/sj.bjc.6690077.
91. Meydani, S. N., Lichtenstein, A. H., Cornwall, S., Meydani, M., Goldin, B. R., Rasmussen, H., et al. (1993). Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J. Clin. Invest. 92, 105-113. doi: 10.1172/JCI116537.
92. Mitsunaga, S., Kinoshita, T., Hasebe, T., Nakagohri, T., Konishi, M., Takahashi, S., et al. (2008). Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas 36, 241-248. doi: 10.1097/MPA.0b013e31815b6b2b.
93. Moses, A. G., Maingay, J., Sangster, K., Fearon, K. C., and Ross, J. A. (2009). Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. 21, 1091-1095. doi: 10.3892/or_00000328.
94. Moses, A. W., Slater, C., Preston, T., Barber, M. D., and Fearon, K. C. (2004). Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br. J. Cancer 90, 996-1002. doi: 10.1038/sj.bjc.6601620.
95. Nelson, K., Walsh, D., Deeter, P., and Sheehan, F. (1994). A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Palliat. Care 10, 14-18.
96. Nitenberg, G., and Raynard, B. (2000). Nutritional support of the cancer patient: issues and dilemmas. Crit. Rev. Oncol. Hematol. 34, 137-168. doi: 10.1016/S1040-8428(00)00048-2.
97. Nixon, D. W., Lawson, D. H., Kutner, M., Ansley, J., Schwarz, M., Heymsfield, S., et al. (1981). Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res. 41, 2038-2045.
98. Olguin, H. C., and Olwin, B. B. (2004). Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev. Biol. 275, 375-388. doi: 10.1016/j.ydbio.2004.08.015.
99. Ottery, F. (1996). Supportive nutritional management of the patient with pancreatic cancer. Oncology (Williston Park) 10, 26-32.
100. Ovesen, L., Allingstrup, L., Hannibal, J., Mortensen, E. L., and Hansen, O. P. (1993). Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J. Clin. Oncol. 11, 2043-2049.
101. Pascual López, A., Roqué i Figuls, M., Urrútia Cuchi, G., Berenstein, E. G., Almenar Pasies, B., Balcells Alegre, M., et al. (2004). Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Symptom Manage. 27, 360-369. doi: 10.1016/j.jpainsymman.2003.09.007.
102. Pausch, T., Hartwig, W., Hinz, U., Swolana, T., Bundy, B. D., Hackert, T., et al. (2012). Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery 152, S81-S88. doi: 10.1016/j.surg.2012.05.028.
103. Pelzer, U., Arnold, D., Gövercin, M., Stieler, J., Doerken, B., Riess, H., et al. (2010). Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer 10:86. doi: 10.1186/1471-2407-10-86.
104. Plata-Salamán, C. R. (1991). Dexamethasone inhibits food intake suppression induced by low doses of interleukin-1 beta administered intracerebroventricularly. Brain Res. Bull. 27, 737-738. doi: 10.1016/0361-9230(91)90055-O.
105. Prado, C. M., Birdsell, L. A., and Baracos, V. E. (2009). The emerging role of computerized tomography in assessing cancer cachexia. Curr. Opin. Support. Palliat. Care 3, 269-275. doi: 10.1097/SPC.0b013e328331124a.
106. Preston, T., Fearon, K. C., McMillan, D. C., Winstanley, F. P., Slater, C., Shenkin, A., et al. (1995). Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br. J. Surg. 82, 229-234. doi: 10.1002/bjs.1800820233.
107. Preston, T., Slater, C., McMillan, D. C., Falconer, J. S., Shenkin, A., and Fearon, K. C. (1998). Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J. Nutr. 128, 1355-1360.
108. Rigas, J. R., Schuster, M., Orlov, S. V., Milovanovic, B., Prabhash, K., Smith, J. T., et al. (2010). Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J. Clin. Oncol. 28:abstract 7622.
109. Russell, S. T., Eley, H., and Tisdale, M. J. (2007). Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal. 19, 1797-1806. doi: 10.1016/j.cellsig.2007.04.003.
110. Russell, S. T., Hirai, K., and Tisdale, M. J. (2002). Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br. J. Cancer 86, 424-428. doi: 10.1038/sj.bjc.6600086.
111. Russell, S. T., and Tisdale, M. J. (2002). Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br. J. Cancer 87, 580-584. doi: 10.1038/sj.bjc.6600493.
112. Rydén, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjölin, E., Isaksson, B., et al. (2008). Lipolysis-not inflammation, cell death, or lipogenesis-is involved in adipose tissue loss in cancer cachexia. Cancer 113, 1695-1704. doi: 10.1002/cncr.23802.
113. Rydén, M., Arvidsson, E., Blomqvist, L., Perbeck, L., Dicker, A., and Arner, P. (2004). Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem. Biophys. Res. Commun. 318, 168-175. doi: 10.1016/j.bbrc.2004.04.010.
114. Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., and Kaplan, G. (1991). Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699-703. doi: 10.1084/jem.173.3.699.
115. Sarraf, P., Frederich, R. C., Turner, E. M., Ma, G., Jaskowiak, N. T., Rivet, D. J., et al. (1997). Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J. Exp. Med. 185, 171-175. doi: 10.1084/jem.185.1.171.
116. Scarlett, J. M., Jobst, E. E., Enriori, P. J., Bowe, D. D., Batra, A. K., Grant, W. F., et al. (2007). Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology 148, 4217-4225. doi: 10.1210/en.2007-0017.
117. Schittek, B., Hipfel, R., Sauer, B., Bauer, J., Kalbacher, H., Stevanovic, S., et al. (2001). Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat. Immunol. 2, 1133-1137. doi: 10.1038/ni732.
118. Schuster, M., Rigas, J. R., Orlov, S. V., Milovanovic, B., Prabhash, K., Smith, J. T., et al. (2010). ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II, randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 28:abstract 7631.
119. Shintani, F., Kanba, S., Nakaki, T., Nibuya, M., Kinoshita, N., Suzuki, E., et al. (1993). Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J. Neurosci. 13, 3574-3581.
120. Simons, J. P., Schols, A. M., Campfield, L. A., Wouters, E. F., and Saris, W. H. (1997). Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin. Sci. (Lond.) 93, 273-277.
121. Simons, J. P., Schols, A. M., Westerterp, K. R., ten Velde, G. P., and Wouters, E. F. (1995). The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia. Am. J. Clin. Nutr. 61, 741-745.
122. Smith, H. J., and Tisdale, M. J. (2003). Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br. J. Cancer 89, 1783-1788. doi: 10.1038/sj.bjc.6601328.
123. Smith, H. J., Wyke, S. M., and Tisdale, M. J. (2004). Role of protein kinase C and NF-kappaB in proteolysis-inducing factor-induced proteasome expression in C(2)C(12) myotubes. Br. J. Cancer 90, 1850-1857. doi: 10.1038/sj.bjc.6601767.
124. Strassmann, G., Fong, M., Kenney, J. S., and Jacob, C. O. (1992). Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89, 1681-1684. doi: 10.1172/JCI115767.
125. Suzuki, H., Asakawa, A., Amitani, H., Fujitsuka, N., Nakamura, N., and Inui, A. (2013). Cancer cachexia pathophysiology and translational aspect of herbal medicine. Jpn. J. Clin. Oncol. 43, 695-705. doi: 10.1093/jjco/hyt075.
126. Tan, B. H., Birdsell, L. A., Martin, L., Baracos, V. E., and Fearon, K. C. (2009). Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 15, 6973-6979. doi: 10.1158/1078-0432.CCR-09-1525.
127. Tisdale, M. J. (1996). Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 12, S31-S33. doi: 10.1016/0899-9007(95)00066-6.
128. Tisdale, M. J., and Beck, S. A. (1991). Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem. Pharmacol. 41, 103-107. doi: 10.1016/0006-2952(91)90016-X.
129. Todorov, P., Cariuk, P., McDevitt, T., Coles, B., Fearon, K., and Tisdale, M. (1996). Characterization of a cancer cachectic factor. Nature 379, 739-742. doi: 10.1038/379739a0.
130. Todorov, P. T., Deacon, M., and Tisdale, M. J. (1997). Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J. Biol. Chem. 272, 12279-12288. doi: 10.1074/jbc.272.19.12279.
131. Todorov, P. T., McDevitt, T. M., Meyer, D. J., Ueyama, H., Ohkubo, I., and Tisdale, M. J. (1998). Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res. 58, 2353-2358.
132. Tsoli, M., Moore, M., Burg, D., Painter, A., Taylor, R., Lockie, S. H., et al. (2012). Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 72, 4372-4382. doi: 10.1158/0008-5472.CAN-11-3536.
133. Tuca, A., Jimenez-Fonseca, P., and Gascón, P. (2013). Clinical evaluation and optimal management of cancer cachexia. Crit. Rev. Oncol. Hematol. 88, 625-636. doi: 10.1016/j.critrevonc.2013.07.015.
134. Wallace, A. M., Sattar, N., and McMillan, D. C. (1998). Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin. Cancer Res. 4, 2977-2979.
135. Watchorn, T. M., Dowidar, N., Dejong, C. H., Waddell, I. D., Garden, O. J., and Ross, J. A. (2005). The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. Int. J. Oncol. 27, 1105-1111.
136. Watchorn, T. M., Waddell, I., Dowidar, N., and Ross, J. A. (2001). Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J. 15, 562-564. doi: 10.1096/fj.00-0534fje.
137. Westman, G., Bergman, B., Albertsson, M., Kadar, L., Gustavsson, G., Thaning, L., et al. (1999). Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. Eur. J. Cancer 35, 586-595. doi: 10.1016/S0959-8049(98)00398-0.
138. Whitehouse, A. S., Khal, J., and Tisdale, M. J. (2003). Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway. Br. J. Cancer 89, 737-745. doi: 10.1038/sj.bjc.6601184.
139. Whitehouse, A. S., and Tisdale, M. J. (2003). Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br. J. Cancer 89, 1116-1122. doi: 10.1038/sj.bjc.6601132.
140. Wigmore, S. J., Barber, M. D., Ross, J. A., Tisdale, M. J., and Fearon, K. C. (2000b). Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr. Cancer 36, 177-184. doi: 10.1207/S15327914NC3602_6.
141. Wigmore, S. J., Falconer, J. S., Plester, C. E., Ross, J. A., Maingay, J. P., Carter, D. C., et al. (1995). Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br. J. Cancer 72, 185-188. doi: 10.1038/bjc.1995.300.
142. Wigmore, S. J., Fearon, K. C., Maingay, J. P., and Ross, J. A. (1997a). Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin. Sci. (Lond.) 92, 215-221.
143. Wigmore, S. J., Plester, C. E., Ross, J. A., and Fearon, K. C. (1997b). Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br. J. Surg. 84, 196-197. doi: 10.1002/bjs.1800840214.
144. Wigmore, S. J., Ross, J. A., Falconer, J. S., Plester, C. E., Tisdale, M. J., Carter, D. C., et al. (1996). The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12, S27-S30. doi: 10.1016/0899-9007(95)00078-X.
145. Wigmore, S. J., Todorov, P. T., Barber, M. D., Ross, J. A., Tisdale, M. J., and Fearon, K. C. (2000b). Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br. J. Surg. 87, 53-58. doi: 10.1046/j.1365-2168.2000.01317.x.
146. Willox, J. C., Corr, J., Shaw, J., Richardson, M., Calman, K. C., and Drennan, M. (1984). Prednisolone as an appetite stimulant in patients with cancer. Br. Med. J. (Clin. Res. Ed.). 288, 27. doi: 10.1136/bmj.288.6410.27.
147. Wisse, B. E., Frayo, R. S., Schwartz, M. W., and Cummings, D. E. (2001). Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142, 3292-3301. doi: 10.1210/endo.142.8.8324.
148. Wyke, S. M., Khal, J., and Tisdale, M. J. (2005). Signalling pathways in the induction of proteasome expression by proteolysis-inducing factor in murine myotubes. Cell Signal. 17, 67-75. doi: 10.1016/j.cellsig.2004.05.015.
149. Wyke, S. M., and Tisdale, M. J. (2005). NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br. J. Cancer 92, 711-721. doi: 10.1038/sj.bjc.6602402.
150. Zamanian-Daryoush, M., Mogensen, T. H., DiDonato, J. A., and Williams, B. R. (2000). NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol. Cell Biol. 20, 1278-1290. doi: 10.1128/MCB.20.4.1278-1290.2000.
151. Zhang, H. H., Halbleib, M., Ahmad, F., Manganiello, V. C., and Greenberg, A. S. (2002). Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929-2935. doi: 10.2337/diabetes.51.10.2929.
152. Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., et al. (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543. doi: 10.1016/j.cell.2010.07.011.